DE60333742D1 - Verwendung einer kombination von l-carnitin, acetyl l-carnitin und propionyl l-carnitin zur behandlung von oligoasthenoteratospermia - Google Patents

Verwendung einer kombination von l-carnitin, acetyl l-carnitin und propionyl l-carnitin zur behandlung von oligoasthenoteratospermia

Info

Publication number
DE60333742D1
DE60333742D1 DE60333742T DE60333742T DE60333742D1 DE 60333742 D1 DE60333742 D1 DE 60333742D1 DE 60333742 T DE60333742 T DE 60333742T DE 60333742 T DE60333742 T DE 60333742T DE 60333742 D1 DE60333742 D1 DE 60333742D1
Authority
DE
Germany
Prior art keywords
carnitine
propionyl
acetyl
combination
oligoasthenoteratospermia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60333742T
Other languages
German (de)
English (en)
Inventor
Giorgio Cavallini
Giulio Biagiotti
Aleardo Koverech
Francesca Sardelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE60333742D1 publication Critical patent/DE60333742D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60333742T 2002-04-09 2003-04-08 Verwendung einer kombination von l-carnitin, acetyl l-carnitin und propionyl l-carnitin zur behandlung von oligoasthenoteratospermia Expired - Lifetime DE60333742D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002RM000194A ITRM20020194A1 (it) 2002-04-09 2002-04-09 Composizione utile per aumentare la concentrazione e la motilita' degli spermatozoi e migliorarne la morfologia nell'uomo.
PCT/IT2003/000214 WO2003084526A1 (en) 2002-04-09 2003-04-08 Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia

Publications (1)

Publication Number Publication Date
DE60333742D1 true DE60333742D1 (de) 2010-09-23

Family

ID=11456235

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60333742T Expired - Lifetime DE60333742D1 (de) 2002-04-09 2003-04-08 Verwendung einer kombination von l-carnitin, acetyl l-carnitin und propionyl l-carnitin zur behandlung von oligoasthenoteratospermia

Country Status (19)

Country Link
US (2) US20050107470A1 (enExample)
EP (1) EP1492521B1 (enExample)
JP (1) JP4663987B2 (enExample)
KR (1) KR20040098005A (enExample)
CN (1) CN1330301C (enExample)
AT (1) ATE476974T1 (enExample)
AU (1) AU2003224443B2 (enExample)
BR (1) BR0309055A (enExample)
CA (1) CA2478674C (enExample)
CY (1) CY1111273T1 (enExample)
DE (1) DE60333742D1 (enExample)
DK (1) DK1492521T3 (enExample)
ES (1) ES2350338T3 (enExample)
IT (1) ITRM20020194A1 (enExample)
MX (1) MXPA04009763A (enExample)
PL (1) PL214859B1 (enExample)
PT (1) PT1492521E (enExample)
SI (1) SI1492521T1 (enExample)
WO (1) WO2003084526A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776913B2 (en) 2002-12-13 2010-08-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Carnitines for treating or preventing disorders caused by andropause
ES2587977T3 (es) * 2009-05-01 2016-10-28 Celloxess Llc Tratamiento de la infertilidad masculina secundaria al estrés oxidativo de esperma
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
CN108041588A (zh) * 2017-12-08 2018-05-18 冯纪敏 一种含有海藻糖的组合物及其应用
CN109999042B (zh) * 2019-05-16 2021-05-18 北京华睿鼎信科技有限公司 包含脱氢表雄酮或其硫酸酯、左卡尼汀、乙酰左卡尼汀或它们的可药用盐的组合物及其应用
CN118435893B (zh) * 2024-05-17 2025-12-19 北部湾大学 L-乙酰肉碱提升香港牡蛎繁殖性能的方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1249462B (it) * 1991-10-21 1995-02-23 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e acil l-carnitine nel trattamento delle oligoastenospermie idiopatiche.
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
IT1295408B1 (it) * 1997-10-03 1999-05-12 Sigma Tau Ind Farmaceuti Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
GB9721746D0 (en) 1997-10-15 1997-12-10 Panos Therapeutics Limited Compositions
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
ITRM20010029A1 (it) * 2001-01-23 2002-07-23 Aldo Fassi Sali metallici di carnitine utili come integratori dietetici/nutrizionali o come farmaci, composizioni che li contengono e procedimenti per
ITRM20020055A1 (it) 2002-02-04 2003-08-04 Aldo Fassi Sali metallici di carnitine, integratori dietetici/nutritivi che li contengono e kit dietetici per contrastare disturbi sessuali in soggetti

Also Published As

Publication number Publication date
US20050107470A1 (en) 2005-05-19
ES2350338T3 (es) 2011-01-21
AU2003224443A1 (en) 2003-10-20
BR0309055A (pt) 2005-02-22
ITRM20020194A0 (it) 2002-04-09
WO2003084526A1 (en) 2003-10-16
DK1492521T3 (da) 2010-11-22
MXPA04009763A (es) 2004-12-13
EP1492521B1 (en) 2010-08-11
ATE476974T1 (de) 2010-08-15
HK1078460A1 (en) 2006-03-17
SI1492521T1 (sl) 2010-12-31
PL214859B1 (pl) 2013-09-30
CN1330301C (zh) 2007-08-08
CY1111273T1 (el) 2015-08-05
CN1638754A (zh) 2005-07-13
CA2478674A1 (en) 2003-10-16
PL372924A1 (en) 2005-08-08
JP4663987B2 (ja) 2011-04-06
AU2003224443B2 (en) 2008-09-11
PT1492521E (pt) 2010-11-11
US20090012169A1 (en) 2009-01-08
ITRM20020194A1 (it) 2003-10-09
US8415392B2 (en) 2013-04-09
JP2006505499A (ja) 2006-02-16
KR20040098005A (ko) 2004-11-18
CA2478674C (en) 2010-10-19
EP1492521A1 (en) 2005-01-05

Similar Documents

Publication Publication Date Title
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE50310516D1 (de) Fredericamycin-derivate
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
ATE458731T1 (de) Pyrimidin-derivate zur behandlung von anormalem zellwachstum
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
ATE400564T1 (de) Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE476974T1 (de) Verwendung einer kombination von l-carnitin, acetyl l-carnitin und propionyl l-carnitin zur behandlung von oligoasthenoteratospermia
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE510543T1 (de) Verwendung cilobradines oder seiner pharmazeutisch annehmbaren salze für die behandlung oder prävention von herzinsuffizienz